Morphine and morphine-6-glucuronide in the plasma and cerebrospinal fluid of children

British Journal of Clinical Pharmacology

Volumn 48, Issue 1, 1999, Pages 37-42

  Hain, Richard D W ^a,c   Hardcastle, A ^b   Pinkerton, C R ^b   Aherne, G W ^b  

^a LLANDOUGH HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Cerebrospinal fluid; Children; Morphine; Morphine 6 glucuronide; Plasma

Indexed keywords

MORPHINE; MORPHINE 6 GLUCURONIDE; OPIATE;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; COMPARTMENT MODEL; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SCHOOL CHILD;

AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFANT; MALE; MORPHINE; MORPHINE DERIVATIVES;

EID: 0032986840     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00948.x     Document Type: Article

References (50)

1. 1 Shimomura, K, Kamata, O, Ueki, S, Ida, S, Oguri, K. Analgesic effect of morphine glucuronides. Tohoku J Exp Med 1971; 105: 45-52.
2. 2 Pasternak, GW, Bodnar, RJ, Clark, JA, Inturrisi, CE. Morphine-6-glucuronide, a potent mu agonist. Life Sci 1987; 41: 2845-2849.
3. 3 Abbott, FV, Palmour, RM. Morphine-6-glucuronide: analgesic effects and receptor binding profile in rats. Life Sci 1988; 43: 1685-1695.
4. 4 Paul, D, Standifer, KM, Inturrisi, CE, Pasternak, GW. Pharmacological characterization of morphine -6-beta glucuronide, a very potent morphine metabolite. J Pharmacol Exp Ther 1989; 251: 477-483.
5. 5 Gong, QL, Hedner, T, Hedner, J, Bjorkman, R, Nordberg, G. Antinociceptive and ventilatory effects of the morphine metabolites: morphine-6-glucuronide and morphine-3-glucuronide. Eur J Pharmacol 1991; 193: 47-56.
6. 6 Osborne, R, Joel, S, Trew, D, Slevin, M. Analgesic activity of morphine-6-glucuronide. Lancet 1988; i: 828.
7. 7 Foley, KM, Portenoy, RK, Thaler, HT, Friedlander Klar, H, Inturrisi, CE. The metabolite, morphine 6 glucuronide, contributes to the analgesic effects of morphine. Proc Am Soc Clin Oncol 1991; 10: 97.
8. 8 Osborne, R, Thompson, P, Joel, S, Trew, D, Patel, N, Slevin, M. The analgesic activity of morphine-6-glucuronide. Br J Clin Pharmacol 1992; 34: 130-138.
9. 9 Davis, CL. Toxicity and pharmacokinetics of morphine and morphine-6-glucuronide. Br J Anaesthesia 1991; 67: 362-363.
10. 10 Peat, SJ, Hanna, MH, Knibb, AA, Ponte, J. Morphine-6-glucuronide: effect on ventilation in normal volunteers. Pain 1991; 45: 101-104.
11. 11 Hanna, MH, Peat, SJ, Knibb, A, Fung, C. Disposition of morphine-6-glucuronide and morphine in healthy volunteers. Br J Anaesth 1991; 64: 547-550.
12. 12 Thompson, PI, John, I, Wedzicha, JA, Slevin, ML. Comparison of the respiratory depression induced by morphine and its active metabolite morphine-6-glucuronide. Br J Cancer 1990; 62: 484.
13. 13 Hucks, D, Thompson, PI, McLoughlin, L, et al. Explanation at the opioid receptor level for differing toxicity of morphine and morphine-6-glucuronide. Br J Cancer 1992; 65: 122-126.
14. 14 Pasternak, GW, Wood, PJ. Minireview: multipe mu opiate receptors. Life Sci 1986; 38: 1889.
15. 15 Yaster, M, Deshpande, JK, Maxwell, LG. The pharmacologic management of pain in children. Comp Ther 1989; 15: 14-26.
16. 16 Chapman, DJ, Joel, SP, Aherne, GW. Evaluation of a differential radioimmunoassay technique for the determination of morphine and morphine-6-glucuronide in human plasma. J Pharmaceut Biomed Anal 1994; 12: 353-360.
17. 17 Chapman, DJ, Cross, MJ, Joel, SP, Aherne, GW. A specific radioimmunoassay for the determination of morphine-6-glucuronide in human plasma. Ann Clin Biochem 1995; 32: 297-302.
18. 18 Joel, SP, Osborne, RJ, Slevin, ML. An improved method for the simultaneous determination of morphine and its principal glucuronide metabolites. J Chromatogr 1988; 430: 394-399.
19. 19 Dahlström, B, Bolme, P, Feychting, H, Noack, G, Paalzow, L. Morphine pharmacokinetics in children. Clin Pharmacol Ther 1979; 26: 354-365.
20. 20 Chinyanga, HM, Vandenberge, H, Bohn, D, Macleod, S, Soldin, S. Pharmacokinetics of morphine in young children following cardiac surgery. Anesthesiol 1983; 59: A447.
21. 21 Vanderberghe, H, MacLeod, S, Chinyanga, M, Endrenyi, L, Soldin, S. Pharmacokinetics of intravenous morphine in balanced anesthesia: studies on children. Drug Metab Rev 1983; 14: 887-903.
22. 22 Nahata, MC, Miser, AW, Reuning, RH. Variation in morphine pharmacokinetics in children with cancer. Dev Pharmacol Therapeutics 1985; 8: 182-188.
23. 23 Greene, RF, Miser, AW, Lester, CM, Balis, TM, Poplack, DG. Cerebrospinal fluid and plasma pharmacokinetics of morphine infusions in pediatric cancer patients and rhesus monkeys. Pain 1987; 30: 339-348.
24. 24 Lynn, AM, Slattery, JT. Morphine pharmacokinetics in early infancy. Anesthesiol 1987; 66: 136-139.
25. 25 Olkkola, KT, Maunskela, E-L, Korpela, R, Rosenberg, PH. Kinetics and dynamics of postoperative intravenous morphine in children. Clin Pharmacol Ther 1988; 44: 128-136.
26. 26 Choonara, IA, McKay, P, Hain, R, Rane, A. Morphine metabolism in children. Br J Clin Pharmacol 1989; 28: 599-604.
27. 27 McRorie, TI, Lynn, AM, Nespeca, MK, Opheim, KE, Slattery, JT. The maturation of morphine clearance and metabolism. Am J Dis Childhood 1992; 146: 972-976.
28. 28 Robieux, IC, Kellner, JD, Coppes, MJ, et al. Analgesia in children with sickle cell crisis: comparison of intermittent opioids versus continuous infusion of morphine and placebo controlled study of oxygen inhalation. Pediatric Hematolgy Oncol 1992; 9: 317-326.
29. 29 Stanski, DR, Greenblatt, DJ, Lowenstein, E. Kinetics of intravenous and instramuscular morphine. Clin Pharmacol Ther 1978; 24: 52-59.
30. 30 Murphy, MR, Hug, CC. Pharmacokinetics of intravenous morphine in patients anaesthetised with enflurane-nitrous oxide. Anesthesiol 1981; 54: 187.
31. 31 Aitkenhead, AR, Vater, M, Achola, K, Cooper, CMS, Smith, G. Pharmacokinetics of single-dose iv morphine in normal volunteers and patients with end-stage renal failure. Br J Anaesth 1984; 56: 813-819.
32. 32 Nordberg, G, Borg, L, Hedner, T, Mellstrand, T. CSF and plasma pharmacokinetics of intramuscular morphine. Eur J Clin Pharmacol 1985; 27: 677-681.
33. 33 Bhat, R, Chari, G, Gulati, A, Aldana, O, Velamati, R, Bhargava, H. Pharmacokinetics of a single dose of morphine in preterm infants during the first week of life. J Pediatrics 1990; 117: 477-481.
34. 34 Barrett, DA, Elias-Jones, AC, Rutter, N, Shaw, PN, Davis, SS. Morphine kinetics after diamorphine infusion in premature neonates. Br J Clin Pharmacol 1991; 32: 31-37.
35. 35 Pokela, M-L, Olkkola, KT, Seppälä, T, Koivisto, M. Age-related morphine kinetics in infants. Dev Pharmacol Ther 1993; 20: 26-34.
36. 36 Venn, R, Michalkiewicz, A, Hardy, P, Wells, C. Concentrations of morphine, morphine metabolites and peptides in human CSF and plasma. Pain 1990; 5: S188.
37. 37 Hand, CW, Blunnie, WP, Claffey, LP, McShane, AJ, McQuay, HJ, Moore, RA. Potential analgesic contribution from morphine-6-glucuronide in CSF. Lancet 1987; 2: 1207-8.
38. 38 Hoskin, PJ, Hanks, GW, Aherne, GW, Chapman, D, Littleton, P, Filshie, J. The bioavailability and pharmacokinetics of morphine after intravenous, oral and buccal administration in healthy volunteers. Br J Clin Pharmacol 1989; 27: 499-505.
39. 39 Pacifici, GM, Säwe, J, Kager, L, Rane, A. Morphine glucuronidation in human fetal and adult liver. Eur J Clin Pharmacol 1982; 22: 553-558.
40. 40 Carrupt, P-A, Testa, B, Bechalany, A, El Tayar, N, Descas, P, Perrissoud, D. Morphine-6-glucuronide and morphine 3-glucuronide as molecular chameleons with unexpected lipophilicity. J Med Chem 1991; 34: 1272-1275.
41. 41 Choonara, I, Lawrence, A, Michalkiewicz, A, Bowhay, A, Ratcliffe, J. Morphine metabolism in neonates and infants. Br J Clin Pharmacol 1992; 34: 434-437.
42. 42 Hartley, R, Green, M, Quinn, M, Levene, MI. Pharmacokinetics of morphine infusion in premature neonates. Arch Dis Childhood 1993; 69: 55-58.
43. 43 Hartley, R, Quinn, M, Green, M, Levene, MI. Morphine glucuronidation in premature neonates. Br J Clin Pharmacol 1993; 35: 314-317.
44. 44 Osborne, R, Joel, S, Trew, D, Slevin, M. Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Ther 1990; 47: 12-19.
45. 45 Sear, JW, Hand, CW, Moore, RA, McQuay, HJ. Studies on morphine disposition: influence of general anaesthesia on plasma concentrations of morphine and its metabolites. Br J Anaesth 1989; 62: 22-27.
46. 46 Hanks, GW, Hoskin, PJ, Aherne, GW, Turner, P, Poulain, P. Explanation for potency of repeated oral doses of morphine. Lancet 1987; ii: 723-726.
47. 47 Portenoy, RK, Khan, E, Layman, M, et al. Chronic morphine therapy for cancer pain: plasma and cerebrospinal fluid morphine and morphine-6-glucuronide concentrations. Neurol 1991; 41: 1457-1461.
48. 48 Portenoy, RK, Foley, KM, Stulman, J, et al. Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: plasma profiles, steady-state concentrations and the consequences of renal failure. Pain 1991; 47: 13-19.
49. 19 Hoskin, PJ, Hanks, GW, Heron, CW, Aherne, GW, Chapman, D. M6G and its analgesic action in chronic use. Clin J Pain 1989; 5: 199-200.
50. 50 Portenoy, RK. Management of common opioid side effects during long-term therapy of cancer pain. Ann Acad Med 1994; 23: 160-170.